



Pressuregarment therapy for preventing
hypertrophic scarring after burn injury





None: All rights reserved
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Harris, IM, Lee, KC, Deeks, J, Moore, D, Moiemen, N & Dretzke, J 2020, 'Pressuregarment therapy for
preventing hypertrophic scarring after burn injury', Cochrane Database of Systematic Reviews, vol. 2020, no. 1,
CD013530. https://doi.org/10.1002/14651858.CD013530
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This Protocol of a Cochrane Review was published in the Cochrane Database of Systematic Reviews 2020, Issue 1. Cochrane Protocols
and Reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Database of Systematic





Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.




Cochrane Database of Systematic Reviews
 
Pressure-garment therapy for preventing hypertrophic scarring
aer burn injury (Protocol)
 
  Harris IM, Lee KC, Deeks JJ, Moore DJ, Moiemen NS, Dretzke J  
  Harris IM, Lee KC, Deeks JJ, Moore DJ, Moiemen NS, Dretzke J. 
Pressure-garment therapy for preventing hypertrophic scarring a'er burn injury. 




Pressure-garment therapy for preventing hypertrophic scarring aer burn injury (Protocol)
 








Cochrane Database of Systematic Reviews









CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 11
DECLARATIONS OF INTEREST..................................................................................................................................................................... 12
SOURCES OF SUPPORT............................................................................................................................................................................... 12
Pressure-garment therapy for preventing hypertrophic scarring aer burn injury (Protocol)









Cochrane Database of Systematic Reviews
[Intervention Protocol]
Pressure-garment therapy for preventing hypertrophic scarring aer
burn injury
Isobel M Harris1, Kwang Chear Lee2, Jonathan J Deeks1, David J Moore1, Naiem S Moiemen3, Janine Dretzke1
1Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 2Department of Burns and Plastic Surgery, Queen
Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 3Burn Centre, University Hospitals
Birmingham NHS Foundation Trust, Birmingham, UK
Contact address: Janine Dretzke, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
j.dretzke@bham.ac.uk.
Editorial group: Cochrane Wounds Group
Publication status and date: New, published in Issue 1, 2020.
Citation: Harris IM, Lee KC, Deeks JJ, Moore DJ, Moiemen NS, Dretzke J. Pressure-garment therapy for preventing hypertrophic scarring
a'er burn injury. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No.: CD013530. DOI: 10.1002/14651858.CD013530.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the eEects of pressure garment therapy for the prevention of hypertrophic scarring a'er burn injury.
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B A C K G R O U N D
Description of the condition
Burn damage to skin, caused by thermal, electrical or chemical
sources, is a common injury worldwide (Peck 2011). In 2004,
approximately 11 million people suEered a burn requiring medical
attention globally (WHO 2008). It is estimated that there are
over 300,000 deaths from burn injuries every year, with the
vast majority (over 95%) occurring in low- and middle-income
countries (WHO 2018). A recent systematic review found that the
incidence and severity of burns occurring in high-income countries
are on a downward trend attributed to advances in burn care,
socioeconomic development, and burn prevention programmes,
but evidence for low- and middle-income countries is lacking
(Smolle 2017). Most burns are not fatal, but the resultant scarring
can cause both cosmetic and functional problems (Ripper 2009).
Whilst scar formation is an inevitable consequence of injury to
the skin (Urioste 1999), in some individuals failure of normal
wound-healing processes results in excessive scar tissue formation,
termed 'hypertrophic scarring' (Atiyeh 2007). The exact mechanism
resulting in hypertrophic scar formation is poorly understood, but
there is some evidence to suggest that derailed immunological
responses are responsible for an exaggerated inflammatory phase
early in the wound-healing process (Van der Veer 2009). Estimates
suggest that hypertrophic scarring aEects 1.5% to 4.5% of the
general population, with hypertrophic scarring following a burn
injury aEecting 32% to 67% of people with burns (Atiyeh 2007).
Hypertrophic scarring is red, thick, and rigid, and causes a variety
of problems including pain, itching, and reduced movement
in aEected areas (Bloemen 2009; Friedstat 2014). It tends to
occur within four to eight weeks following injury (Gauglitz 2011).
Keloid scarring may also occur a'er burn injury in genetically
susceptible individuals but is relatively rare. Keloid scarring is
similar in appearance to hypertrophic scarring, but keloid scarring
spreads beyond the margins of the original wound whereas
hypertrophic scarring does not. Keloid scarring can develop later
than hypertrophic scarring, up to several years a'er the initial
injury (Gauglitz 2011). Keloid scars are treated very diEerently to
hypertrophic scars (Gauglitz 2013), and as such will not be the
subject of this review.
Many factors are involved in the development of hypertrophic
scarring, such as age, ethnic group, and hormone levels, as
well as the burn size, thickness, and location (Niessen 1999).
The involvement of these factors in hypertrophic scar formation
is poorly understood, and robust evidence is currently lacking
(Butzelaar 2016). However, it is generally accepted that the most
important factor in predicting the development of hypertrophic
scarring is healing time, which is related to burn size and thickness
(Chipp 2017; Miller 2005).
There are many methods of assessing scars based on various
factors such as colour, texture, and thickness. The most commonly
used subjective assessment scales are the Patient and Observer
Scar Assessment Scale (POSAS) and the Vancouver Scar Scale
(VSS) (Bae 2014). Laser imaging, ultrasound imaging, cutometer,
colorimetry, and 3D cameras can also be used for objective scar
assessment (Lee 2016). Current recommendations are that a panel
of devices should be used for comprehensive scar assessment (Lee
2016).
Description of the intervention
The most commonly used method for the prevention and
treatment of hypertrophic scarring is pressure-garment therapy
(PGT) (Anzarut 2009; Engrav 2010; Ward 1991), which costs the
NHS approximately GBP 2.2 million a year (Moiemen 2018). PGT
involves the wearing of tight elastic garments in the area of the
burn as soon as wound healing has occurred and pressure therapy
can be tolerated. The garments should be worn for 23 hours a
day (allowing removal for up to one hour for bathing and personal
care), for an average of 12 to 18 months, depending on scar severity
(Anzarut 2009; Yildiz 2007). There are two main types of pressure
garments: ready-to-wear/pre-sized garments and custom-made
garments. Ready-to-wear garments have the advantages of being
immediately available and cheaper than custom-made garments,
but adjustments are usually required for a better fit and to ensure
they exert enough pressure (Macintyre 2006). The exact amount of
pressure required is not known (Atiyeh 2013; Huang 2013), but it
is thought that less than 15 mmHg and more than 40 mmHg does
not result in the required eEect (Bloemen 2009; Park 2011). Most
typically, pressures of 15 to 25 mmHg are used in clinical settings
(Ai 2017; Sharp 2007). There is some evidence to indicate that
pressures over 30 mmHg are harmful (Ai 2017). The exact amount
of pressure exerted by a garment is o'en not known, particularly
where the reduction method is used for manufacture. With this
method the dimensions of the body part with the burn wound are
measured and the garment is made with a 10% to 20% reduction
factor for that measurement (Atiyeh 2013). Exerted pressure may
also not be uniform and depends on factors such as curvature of the
body part, and the underlying type of tissue; there is also a loss of
tension over time (Atiyeh 2013).
Wearing pressure garments can be challenging for several reasons,
including discomfort (itching, pain, sweating), embarrassment at
wearing the visible garments, and the demands of the duration
and intensity of treatment (Johnson 1994; Macintyre 2006; Ripper
2009). Such challenges can result in treatment dropout rates of
30% to 59% in adults (Ripper 2009). Factors shown to help improve
patient adherence to PGT include good social support and a good
doctor-patient relationship (DiMatteo 2004; Moiemen 2018; Ripper
2009).
Other forms of treatment, used independently of or in conjunction
with PGT, include silicone sheets/sprays/gels applied to the burn,
corticosteroid injections, and laser therapy (Bloemen 2009). These
treatments are thought to variously influence wound collagen
remodeling, inflammation or angiogenesis or both, but the exact
mechanisms of action have not been fully elucidated (Atiyeh 2013).
They are most likely to be used in combination with PGT rather than
as an alternative.
How the intervention might work
PGT is thought to work in two ways, by aEecting collagen
remodelling during the wound-healing process. Firstly, the tight
pressure restricts blood flow, and therefore oxygen availability, to
the scar, which is thought to accelerate the maturation of the scar
(Clark 1996; Ripper 2009). Secondly, the constant pressure exerted
on the scar tissue forces the collagen fibres of the new tissue to grow
systematically and more in line with the normal pattern of healthy
skin fibres (Clark 1996; Ripper 2009). Pressure garment therapy is
therefore most eEective if initiated when the wound is fully closed
but the scar is still fragile and likely to break down (Bloemen 2009).
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For best results the pressure garments need to be worn until scar
maturation.
Why it is important to do this review
Scarring can have serious functional and cosmetic implications,
and may negatively impact upon patients’ quality of life (Atiyeh
2013; Ripper 2009). Scarring is very visible due to the diEerences
in colour, pigmentation, and texture of aEected tissue and can
lead to psychological problems such as stigmatisation and low
self-esteem. Scarring can also be very uncomfortable in terms of
pain, pruritus, and dryness (Ai 2017). Interventions aim to improve
functionality in terms of both work and leisure activities (Atiyeh
2013).
PGT in its currently-used form originated in the 1970s from a
leading burns centre in the USA where immediate improvement of
hypertrophic scarring was observed in individuals with major burns
(Atiyeh 2013). The practice spread widely to other centres in the USA
and beyond, despite the lack of well-designed clinical trials to show
the eEicacy of PGT (Moiemen 2018). This was probably facilitated
by the ready availability of the garments, and substantial industry
involvement and drive towards commercialisation (Linares 1993).
PGT is now standard care in almost all burn centres globally, but
there is continued uncertainty around its eEectiveness, including
perceived benefit to its recipients (Moiemen 2018).
Laser treatment and percutaneous needling are gaining
recognition as viable options to treat hypertrophic scarring, but
these treatments are used only a'er scar maturation (Finnerty
2016).
A systematic review (Anzarut 2009) based on six studies was
unable to draw definitive conclusions. A more recent systematic
review (Ai 2017) included 12 studies and found some evidence of
improvement as measured by the VSS score and in pigmentation,
redness and scar hardness. Inclusion was limited to studies using
a pressure of 15 to 25 mmHg. There appeared to be insuEicient
consideration of heterogeneity in the analyses, with studies being
pooled regardless of comparator (no and low pressure), age
(adults and children) or co-intervention (e.g. pressure therapy and
silicone). It was also unclear if data included in meta-analyses
were based on intention-to-treat analyses, and whether studies
not included in the meta-analyses reported relevant outcomes.
Adverse events and compliance were also insuEiciently considered.
Since the publication of this systematic review, there has been at
least one other relevant study (Pegasus) (Moiemen 2018) and there
are a number of ongoing studies.
A complete assessment of all the evidence, including full
consideration of heterogeneity (including diEerent levels of
pressure), all comparator groups and all relevant outcomes is
therefore warranted.
O B J E C T I V E S
To assess the eEects of pressure garment therapy for the prevention
of hypertrophic scarring a'er burn injury.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include published and unpublished randomised controlled
trials (RCTs), including (i) between-patient comparisons where
participants are either allocated to the intervention or to a
comparator, and (ii) split-body designs, where diEerent wounds
within the same participant are allocated to diEerent treatments.
We will place no restriction by publication status or language. We
will exclude studies using quasi-randomisation.
Types of participants
We will include RCTs recruiting people in any population or
care setting and with any size, depth or cause of burn (thermal,
electrical, or chemical) who are likely to develop hypertrophic
scarring and who are suitable for hypertrophic scarring prevention
therapy. People likely to develop hypertrophic scarring are those
whose wounds have taken around three or more weeks to heal or
who have received skin gra's as a result of their burn injury. We do
not anticipate health equity issues within the eligible populations.
Types of interventions
We will include studies with PGT (any pressure) alone or in
combination with other scar-management therapies. We will
include any RCT in which the use of PGT (any type or duration of
treatment), a diEerence in pressure or the type of pressure garment
during the treatment period is the only systematic diEerence
between treatment groups.
Types of comparison
Any other type of scar-management treatment not including PGT,
or PGT using a diEerent (lower) pressure, or a diEerent type of
pressure garment. We will not include studies comparing diEerent
durations of the same PGT.
Types of outcome measures
Primary outcomes
The extent of hypertrophic scarring assessed by scar-rating
scales such as the Vancouver Scar Scale (VSS) and the Patient
and Observer Scar Assessment Scale (POSAS) or other verified
assessment scale with results reported as mean and standard
deviation (SD), or median and range. Scar-rating scales attempt
to quantify overall scar severity by measuring a range of scar
parameters, such as thickness, vascularity, pigmentation and
pliability. Some, such as the POSAS, also include pain and pruritus.
There is currently no ‘gold standard’ scar-rating scale, as none are
thought to include all aspects relevant to patient quality of life (e.g.
cosmetic, functional or psychological aspects) (Nguyen 2015).
We will distinguish between outcome reporting in the short term
(less than six months) and longer term (6 - 12 months; 12 - 18
months; > 18 months), as findings are unlikely to be comparable.
Secondary outcomes
• Individual scar parameters (surface area/volume, texture,
thickness, vascularity, pigmentation and pliability), regardless
of how measured (subjective, e.g. observer- or participant-rated,
Pressure-garment therapy for preventing hypertrophic scarring aer burn injury (Protocol)
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or objective, or both, e.g. using a  measurement tool such as a
colorimeter or tonometer)
• Range of movement (ROM) assessment (where the scar is above
a joint), measured using a goniometer
• Pain measured by any relevant scale/tool
• Pruritus measured by any relevant scale/tool
• Adverse events/complications (e.g. wound breakdown and
blistering), where this is reported as the proportion of
participants in each group with an adverse event
• Participant health-related quality of life/health status,
measured using a standardised generic questionnaire such as
EQ-5D, SF-36, SF-12 or SF-6, or wound-specific questionnaires
such as the Burn Specific Health Scale–Brief (BSHS-B)
• Adherence to therapy
• Any other outcome measuring the impact of the burn/scar on the
participant (e.g. the Brisbane Burn Scar Impact Profile)
Outcomes in paediatric trials may be parent-reported. Outcomes
aEecting the participant as a whole (such as quality of life) cannot
be measured where a randomised controlled trial has a split-body
design.
We note that at present there are no clinically-defined minimum
important diEerences or thresholds for either the primary or
secondary outcomes.
Search methods for identification of studies
Electronic searches
We will search the following databases to retrieve reports of
relevant trials:
• the Cochrane Wounds Specialised Register;
• the Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library (latest issue);
• Ovid MEDLINE (from 1946 onwards);
• Ovid Embase (from 1974 onwards);
• EBSCO Cumulative Index to Nursing and Allied Health Literature
(CINAHL Plus); from 1937 onwards.
We have devised a dra' search strategy for CENTRAL which is
displayed in Appendix 1. We will adapt this strategy to search
the Cochrane Wounds Specialised Register, Ovid MEDLINE, Ovid
Embase and EBSCO CINAHL Plus. We will combine the Ovid
MEDLINE search with the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials in MEDLINE: sensitivity-
and precision-maximising version (2008 revision) (Lefebvre 2019).
We will combine the Embase search with the Ovid Embase filter
terms developed by the UK Cochrane Centre (Lefebvre 2019). We
will combine the CINAHL Plus search with the trial filter developed
by Glanville 2019. There will be no restrictions of the searches by
language, date of publication or study setting.
We will also search the following clinical trials registries for ongoing
studies:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (www.who.int/trialsearch).
Searching other resources
We will search the bibliographies of all retrieved and relevant
publications identified by these strategies for further studies. We
will contact experts in the field to ask if they have been involved in
or know of any studies relevant to this review. We will also contact
JOBST®, Jobskin®, Gottfried Medical Inc. and DM Orthotics Ltd. to
ask for information relevant to this review. We do not plan to carry
out any handsearching.
Data collection and analysis
Selection of studies
Two review authors (IMH, KCL) will independently screen titles and
abstracts, using the eligibility criteria described. They will both
screen full texts where a decision cannot be made on the basis of
title or abstract or both, resolving disagreements though discussion
or through consulting a third review author (NM). We will use a
PRISMA flow diagram for documenting the selection process and
reasons for exclusion (Liberati 2009). We will use EndNote X7 to
manage the screening process.
Data extraction and management
Two review authors (IMH, KCL) will independently extract data
using a standardised and piloted data extraction form. We will
resolve disagreements through discussion or through consulting a
third review author (NM or JD). Key data to be extracted will include:
• study characteristics and methods: year of publication, study
design, randomisation method and unit of randomisation, start
date, country of study, setting, length of follow-up;
• participants: number, age, inclusion and exclusion criteria,
percentage male, severity and cause of burn;
• intervention: type of garment, time from 95% healing to starting
PGT, duration of treatment period, pressure used, any other
therapies used;
• comparator therapy: standard care, other therapies, (lower)
pressure used;
• primary and secondary outcomes: method of scar improvement
assessment, how measured, time points measured, scores
at baseline/post-treatment (intervention and control groups),
change scores, summary scores;
• funding and potential conflicts of interest among the study
authors.
We will record the data in Review Manager 5 (Review Manager 2014).
We will contact authors for missing outcome data. 
Assessment of risk of bias in included studies
Two review authors (IMH, KCL) will independently assess risks of
bias of included randomised controlled trials, using the Cochrane
'Risk of bias' tool which is displayed in Appendix 2. Domains relate
to selection bias, performance bias, detection bias, attrition bias
and reporting bias and other potential forms of bias. Due to the
nature of the intervention, it is diEicult to blind participants or
those administering the intervention. Blinding may be possible to
an extent where diEerent pressures are compared (e.g. high versus
lower/ineEective pressure). As pressure garments are by design
tight-fitting, they can leave marks on the skin when removed, so
blind outcome assessment of scars may also be diEicult to achieve.
Review authors will make a decision of ‘low’, ‘high’ or ‘unclear’
Pressure-garment therapy for preventing hypertrophic scarring aer burn injury (Protocol)
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risk of bias based on the criteria given for making 'Risk of bias'
judgements. We will assess risks of bias separately for diEerent
outcomes where there are diEerences in, for example, blinding
and loss to follow-up. We will record reasons underpinning the
decisions. The review authors will resolve disagreements though
discussion or through consulting a third review author (JD).
Measures of treatment e:ect
Most outcomes are likely to be continuous, e.g. changes on scar-
rating or quality-of-life scales, and we will use the mean diEerence
with its 95% confidence interval (MD, 95% CI) for quantitative
synthesis. When comparing the diEerence between groups, we will
give preference to a follow-up score adjusted for baseline (using
ANCOVA) compared with a change score. Where trials measure the
same outcome using diEerent scales, we will consider using the
standardised mean diEerence (SMD, 95% CI) as a summary statistic
in any meta-analysis of such data. We will use the risk ratio (RR, 95%
CI) for dichotomous data (e.g. adverse event data). Where risk ratios
are not reported it may be possible to calculate them from raw data.
We do not anticipate any time-to-event data.
Unit of analysis issues
Studies may randomise participants, but may conduct analysis by
wound/scar. If there is one wound/scar per participant, then the
person will be the unit of analysis. Where randomised participants
have several wounds, they need to be considered as participant
‘clusters’. We will consider whether authors have used analysis
methods to account for such clustering. Where trials include a
mixture of participants with one or more wounds (individual and
clustered data), then we will note this as a concern as part of the
'Risk of bias' assessment.
Studies may also measure within-participant diEerences, where
two or more wounds are treated diEerently, or one half of a wound
is treated diEerently from the other half. Additional 'Risk of bias'
considerations are likely to arise from a within-participant design,
e.g. relating to choice of site for each treatment or blinding of
outcome evaluation across the same site. We will consider whether
paired analysis has been undertaken to account for the within-
participant design and will record this as part of the 'Risk of bias'
assessment.
We will present all data, but we will only take appropriately-
analysed data forward for meta-analysis. If studies use multiple
intervention arms compared with a single control, we will split the
control group to avoid unit-of-analysis errors. If more than one
intervention is used in a treatment arm, we will analyse this as a
single combined treatment (e.g. PGT with silicone).
Dealing with missing data
We will contact authors if relevant outcome data are insuEiciently
reported. We will also contact authors of ongoing trials and
relevant conference abstracts for interim or additional data. Where
measures of variance are missing we will calculate them if possible.
For analyses, we will use data based on an intention-to-treat
analysis where possible, e.g. based on last observation carried
forward (LOCF) for continuous data. If studies have reported
dichotomous outcomes (e.g. the proportions with and without a
certain level of improvement) and there are missing data, we will
assume for the purpose of analysis that the improvement was not
achieved. We will test the impact of this assumption in a sensitivity
analysis where we will assume that the improvement was achieved.
Assessment of heterogeneity
We will consider clinical and methodological heterogeneity before
deciding whether to combine data quantitatively. Sources of
clinical heterogeneity will relate to the type of therapy (e.g. level
of pressure, additional scar-management techniques), comparator
(e.g. alternative pressure, diEerent therapy) and population (aged
16 or under versus adult). There may also be diEerences in
length of follow-up and use of outcome measures, e.g. types
of scar-assessment tool. Methodological heterogeneity will relate
to the type of randomisation, e.g. between participants or
within participant. We will base judgements about statistical
heterogeneity on the Chi2 test and I2 statistic values (Deeks 2017).
Assessment of reporting biases
We will try to minimise reporting biases by searching multiple
databases and clinical trial registries. As part of the 'Risk of bias'
assessment we will look for incompletely-reported or missing
outcome data. We will assess the possible presence of publication
bias using funnel plots where at least 10 studies are included
in a meta-analysis, and will visually inspect the plot for signs of
asymmetry. We will not conduct statistical tests for asymmetry. We
note that, based on scoping searches, there are unlikely to be more
than 10 studies within an individual meta-analysis.
Data synthesis
We will group findings first by comparison (PGT versus standard
care only; PGT versus lower pressure treatment; PGT versus an
alternative intervention; diEerent types of pressure garment) and
then by outcome, and time point (< 6 months; 6 - 12 months;
12 - 18 months; > 18 months). We will undertake meta-analyses
where we consider studies with the same comparator and reporting
the same outcome (and outcome metric) to be reasonably similar
in terms of clinical and methodological characteristics. As there
is likely to be some heterogeneity between studies in terms of
participant and intervention characteristics, we will use a random-
eEects model. A fixed-eEect approach is unlikely to be appropriate,
as the assumption that a single underlying treatment eEect is being
estimated is unlikely to be correct. We will not combine split-body
and standard RCT studies in meta-analyses.
We will also measure statistical heterogeneity, but will not use it to
decide on whether or not to undertake each meta-analysis. Where
we do undertake meta-analyses, we will use the Chi2 test to give an
indication of whether there is statistically significant heterogeneity.
As we expect relatively few studies to be in the individual meta-
analyses (fewer than 10), we will set the significance level at P
< 0.1. We will also use the I2 statistic to quantify the amount
of heterogeneity beyond that expected by chance, and will
use guidance outlined in the Cochrane Handbook for Systematic
Reviews of Interventions to interpret I2 (Deeks 2017).
We will use forest plots to present summary estimates (mean
diEerence or risk ratio) with 95% confident intervals. Where the
same outcome is measured using diEerent scales, we will use the
standardised mean diEerence (SMD, 95% CI) as a summary statistic.
We will also consider the representation of subgroups in forest plots
without overall pooling. Results from studies not included in meta-
analyses will be summarised in tables.
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Subgroup analysis and investigation of heterogeneity
We will explore whether it is possible to subgroup studies by age
(e.g. infants, younger/older children, and adults) and by location of
burn (e.g. limbs, trunk, head, face). Subgrouping by burn severity
is unlikely to be possible, given that burns in a person may be a
mixture of superficial and deep burns. We will present any results
from subgroup analyses undertaken by the primary study authors
where these align with our prespecified subgroups described
above, i.e. age and location of burn.
As described in the Data synthesis section, we will group studies
by length of follow-up time. It is thought that pressure garments
should be used for at least six to 18 months, so outcomes between
studies with short-term (less than six months) and longer-term
follow-up (6 - 12 months; 12 - 18 months; > 18 months) are unlikely
to be comparable. If studies report this, we will also look at whether
there are any diEerences in time from 95% healing to start of PGT,
as the starting point may aEect outcome. We will explore the eEect
of including or excluding studies of diEerent study design (within-
participant or between-participant randomisation) where possible.
We will explore diEerences between subgroups using random-
eEects meta-regression.
Sensitivity analysis
We will use 'Risk of bias' assessment findings to guide
interpretation of our findings. We will consider sensitivity analyses
based on study quality, by removing any studies classified as being
at overall ‘high’ risk of bias. However this will be contingent on
the number of studies in a meta-analysis, the completeness of
reporting of quality criteria and evidence of clear diEerences in the
risk of bias between studies.
We will also explore the eEect of excluding studies where intention-
to-treat data are not available.
'Summary of findings' tables and GRADE assessment of the
certainty of evidence
We will present the main results for the review in 'Summary of
findings' tables, which will include a list of the important outcome
measures, numbers of studies measuring the outcomes and
numbers of participants, measures of eEect (size and uncertainty)
and overall certainty of evidence based on GRADE (Schünemann
2013). We will rate the certainty of the body of evidence as high,
moderate, low, or very low, depending on the directness of the
evidence in addressing the study question/s, the risks of bias
in the included studies (methodological quality), the precision
of eEect estimates, the consistency of the evidence (degree of
heterogeneity), and the risk of publication bias (Schünemann
2013). We will undertake this on an outcome-by-outcome basis. The
absence of clinically-defined minimum important diEerences for
primary or secondary outcomes means it will not be possible to
use this information in making decisions on rating of imprecision.
Where analysis of an outcome is not possible due to lack of data, we
will present the reasons for this in the table.
We plan to include the following outcomes in the 'Summary of
findings' tables:
• Scar improvement assessed by scar-rating scales such as the
Vancouver Scar Scale (VSS) and the Patient and Observer Scar
Assessment Scale (POSAS);




• Adverse events/complications (wound breakdown and
blistering);
• Quality of life;
• Adherence to therapy.
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A P P E N D I C E S
Appendix 1. The Cochrane Central Register of Controlled Trials (CENTRAL) dra search strategy
#1 MeSH descriptor: [Burns] explode all trees
Pressure-garment therapy for preventing hypertrophic scarring aer burn injury (Protocol)









Cochrane Database of Systematic Reviews
#2 (burn or burns or burned or scald* or postburn* or post-burn*):ti,ab,kw
#3 ((thermal or chemical or alkali or acid or electric*) next injur*):ti,ab,kw
#4 #1 or #2 or #3
#5 MeSH descriptor: [Cicatrix] explode all trees
#6 ((hypertroph*) near/3 (cicatri* or scar or scars or scarred or scarring)):ti,ab,kw
#7 #5 or #6
#8 #4 and #7
#9 MeSH descriptor: [Compression Bandages] explode all trees
#10 MeSH descriptor: [Pressure] explode all trees
#11 MeSH descriptor: [Clothing] explode all trees
#12 MeSH descriptor: [Occlusive Dressings] explode all trees
#13 ((pressure or compression or elastic or ace) near/3 (garment* or bandag* or stocking* or hosiery or wrap* or therap*)):ti,ab,kw
#14 (mmHg):ti,ab,kw
#15 (jobskin or jobst or tubigrip or tubi-grip or tubi grip or lymed or tricolast or urgosyval):ti,ab,kw
#16 (PGT):ti,ab,kw
#17 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #8 and #17
Appendix 2. Risk of bias assessment tool for randomised controlled trials
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a
computer random number generator; coin tossing; shuEling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based
on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
InsuEicient information about the sequence generation process provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. envelopes were unsealed, non-opaque, or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
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Unclear
InsuEicient information provided to permit a judgement of low or high risk of bias. This is usually the case if the method of concealment
is not described, or not described in suEicient detail to allow a definite judgement, for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of
blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others
unlikely to introduce bias.
High risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Either of the following:
• InsuEicient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data are unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).
• Missing outcome data are balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is not enough to have a
clinically relevant impact on the intervention eEect estimate.
• For continuous outcome data, a plausible eEect size (diEerence in means or standardised diEerence in means) among missing outcomes
is not enough to have a clinically relevant impact on the observed eEect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following:
• Reason for missing outcome data are likely to be related to the true outcome, with either an imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is enough to induce
clinically relevant bias in the intervention eEect estimate.
• For continuous outcome data, a plausible eEect size (diEerence in means or standardised diEerence in means) among missing outcomes
is enough to induce a clinically relevant bias in the observed eEect size.
• 'As-treated' analysis done with a substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following:
Pressure-garment therapy for preventing hypertrophic scarring aer burn injury (Protocol)









Cochrane Database of Systematic Reviews
• InsuEicient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not stated, no
reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following:
• The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review
have been reported in the prespecified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were
prespecified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s prespecified primary outcomes have been reported.
• One or more primary outcomes is/are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were
not prespecified.
• One or more reported primary outcomes was/were not prespecified (unless clear justification for their reporting is provided, such as
an unexpected adverse eEect).
• One or more outcomes of interest in the review is/are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
InsuEicient information provided to permit a judgement of low or high risk of bias. It is likely that the majority of studies will fall into this
category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insuEicient information to assess whether an important risk of bias exists; or
• insuEicient rationale or evidence that an identified problem will introduce bias.
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